Colorectal Cancer Vulnerabilities Dream Team - Stand Up To Cancer

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Colorectal Cancer Vulnerabilities Dream Team

SU2C Colorectal Cancer Dream Team:
Targeting Genomic, Metabolic, and Immunological
Vulnerabilities of Colorectal Cancer

Grant Term: July 2017–June 2020

The Stand Up To Cancer Colorectal Cancer Treatment Dream Team is taking a broad-spectrum approach by addressing three complementary areas of research that have the potential to impact all stages of the disease. The first two areas of research are on the potential impact of immunotherapy and targeted therapy, and the last area of study will evaluate strategies to target different colorectal cancer subtypes. 

ABOUT THIS TEAM’S RESEARCH

This SU2C Colorectal Cancer Dream Team is focusing on three areas of research that have the potential to impact the treatment of all stages of colorectal cancer.

The first two areas of research examine the potential of immunotherapy and targeted therapy to revolutionize the treatment of colorectal cancer. The team will determine the mechanisms of resistance to immunotherapies and targeted therapies, and devise new strategies to overcome resistance.

The third area of study evaluates strategies to target different colorectal cancer subtypes. Specifically, two major subgroups of colorectal cancer—those with a mutation in the KRAS/BRAF gene, and those with a mutation in the PIK3CA gene—are susceptible to high doses of vitamin C combined with depletion of a nutrient called glutamine.

In animal studies, drugs developed to target these vulnerabilities were able to slow down or cure colorectal cancers of the two subgroups. This team is evaluating whether these promising findings can be transposed to patients with similar genomic abnormalities.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.